05.11.2012 Views

Monthly M&A Insider - Mergermarket

Monthly M&A Insider - Mergermarket

Monthly M&A Insider - Mergermarket

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Germany<br />

Consolidating the German newspaper industry<br />

• Germany’s newspaper industry is highly fragmented and<br />

has always been a likely area for consolidations. The most<br />

controversial consolidation in the German newspaper<br />

market was the acquisition of BV Deutsche Zeitungsholding<br />

by Mecom in 2007.<br />

• In the last few years however, the inability of newspapers<br />

to become profitable online and declining circulation has led<br />

to lower advertising, copy sales, and subscription revenue.<br />

Particularly the decline in advertising revenue has been<br />

exacerbated by the current economic downturn. This,<br />

coupled with the high and inflexible fixed costs newspaper<br />

publishing incurs, has proved a strong incentive for<br />

consolidations, as the industry looks to achieve economies<br />

of scope and scale.<br />

• As one would expect in an industry sensitive to swings in<br />

the economy, the German newspaper industry has shown<br />

increased activity over the past month, with Mecom<br />

selling it’s German operations, including “Berliner Kurier”,<br />

“Berliner Zeitung”, “TIP Verlag GmbH”, and “Hamburger<br />

Morgenpost”, to the German publisher M. DuMont<br />

Schauberg (MDS) for €152m, making MDS Germany’s third<br />

largest newspaper publisher. MDS subsequently<br />

sold a 35% stake of this on to Heinen Verlag, another<br />

German publisher.<br />

• Verlagsgruppe Georg von Holtzbrinck sold the<br />

Verlagsgruppe Handelsblatt (VHB), including<br />

“Handelsblatt”, “Wirtschaftswoche” and “Tagesspiegel”,<br />

and a 50% stake in “Die Zeit” to Dieter von Holtzbrinck<br />

Medien GmbH. Additionally, Stefan von Holtzbrinck,<br />

chairman of the Verlagsgruppe Georg von Holtzbrinck<br />

Verlag is interested in making acquisitions among regional<br />

newspapers and said the company will keep its eyes open.<br />

• Is this trend set to continue? Axel Springer, the listed<br />

German publisher, certainly thinks so. The publisher would<br />

also be interested in buying German regional newspapers<br />

according to chief executive Matthias Doepfner, citing the<br />

global financial crisis as providing good opportunities for<br />

acquisitions in both print and online media.<br />

• Another possible deal looming in the near future could be<br />

the acquisition of Schleswig-Holsteinischer Zeitungsverlag<br />

(SHZ). According to the Financial Times Deutschland, SHZ<br />

is seeking a buyer for itself, in a deal expected to be worth<br />

€ 400m with the rival German publisher Madsack thought<br />

to be a likely buyer.<br />

• Furthermore, smaller family-owned newspaper groups<br />

might come on to the market as they lack successors and<br />

funds for both the expansion into the digital arena and to<br />

survive the economic downturn.<br />

Novartis: Alcon commitment prioritised over<br />

move for Bayer, insider says<br />

• Novartis does not envisage “mega-deals” such as the<br />

acquisition of Bayer, said a Novartis insider. The insider said<br />

Novartis is already well-diversified and also mentioned the<br />

commitment of the Swiss listed pharma company to the<br />

acquisition of Alcon, for which it still has to make another<br />

payment of some $28bn.<br />

• This month, Novartis was rumoured it may offer €42.55<br />

per share for Bayer, the listed German chemicals/<br />

pharmaceuticals company, although no company<br />

spokesperson could confirm or deny the rumours.<br />

• Sector analysts further believe that Novartis could be<br />

planning a move for Austrian vaccines developer Intercell<br />

in due course. The two firms are already involved in a<br />

partnership and a takeover by Novartis was described as<br />

an obvious move. When asked, an Intercell source did not<br />

deny Novartis could be interested in such a move.<br />

• Last month, a Novartis spokesperson had told this news<br />

service that bolt-ons in the range of some CHF 100m<br />

(€66m) are part of the Swiss pharma company’s strategy.<br />

A large acquisition is unlikely to take place in the near<br />

future, the spokesperson added at the time, with reference<br />

to a statement by Novartis’ CEO Daniel Vasella.<br />

<strong>Monthly</strong> M&A report – 111

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!